Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,911
  • Shares Outstanding, K 18,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,890 K
  • 60-Month Beta 0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.63
Trade ADIL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +117,629.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.27 +5.29%
on 07/27/21
3.40 -29.71%
on 07/14/21
-0.55 (-18.71%)
since 07/02/21
3-Month
1.91 +25.13%
on 05/11/21
3.78 -36.77%
on 06/22/21
+0.19 (+8.64%)
since 04/30/21
52-Week
1.14 +109.65%
on 09/24/20
4.00 -40.25%
on 09/29/20
+0.78 (+48.45%)
since 07/31/20

Most Recent Stories

More News
Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that an op-ed from Adial's CEO, William...

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform

Data merits further testing for pain reduction as a possible alternative to opioids

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the Company has entered into...

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
The Phase 3 ONWARD(TM) Trial Meets its Screening Target and Nears Enrollment Completion

Study Drug Continues to Appear to be Well-Tolerated

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
Former member of the National Advisory Council on Drug Abuse (NACDA) and National Institute on Drug Abuse (NIDA) Joins Ehave, Inc; Ehave Appoints Psychopharmacologist, Board-Certified Psychiatrist, And Licensed Physician, Bankole Johnson To Its Medical Advisory Board

Ehave, Inc., (OTC Pink: EHVVF) (the "Company"), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today Dr. Bankole A. Johnson has agreed to join the Company's...

EHVVF : 0.0350 (unch)
ADIL : 2.39 (-2.05%)
Adial Joins Russell Microcap(R) Index

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and...

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has received correspondence...

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
Thinking about buying stock in ContextLogic, Adial Pharmaceuticals, Geron Corp, Orphazyme, or Citius Pharmaceuticals?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, ADIL, GERN, ORPH, and CTXR.

ADIL : 2.39 (-2.05%)
GERN : 1.2500 (+2.46%)
ORPH : 4.75 (-0.63%)
WISH : 10.41 (+4.73%)
CTXR : 1.8900 (unch)
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today...

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)
Adial Pharmaceuticals Comments on Article in 'The Atlantic,' Highlighting the Second Pandemic of Addiction

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and...

ADIL : 2.39 (-2.05%)
ADILW : 0.7101 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 2.53
2nd Resistance Point 2.50
1st Resistance Point 2.44
Last Price 2.39
1st Support Level 2.35
2nd Support Level 2.32
3rd Support Level 2.26

See More

52-Week High 4.00
Fibonacci 61.8% 2.91
Fibonacci 50% 2.57
Last Price 2.39
Fibonacci 38.2% 2.23
52-Week Low 1.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar